If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBOCH.L Regulatory News (BOCH)

  • There is currently no data for BOCH

Update on Project Helix

19 Mar 2019 15:16

RNS Number : 3441T
Bank of Cyprus Holdings PLC
19 March 2019
 

Announcement

 

Update on Project Helix - Agreement for the sale of a portfolio of non-performing loans

 

 

Nicosia, 19 March 2019

 

 

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014

 

 

Further to the announcement of 28 August 20181 in relation to the agreement for the sale of a portfolio of non-performing loans, known as "Project Helix", or the "Transaction", Bank of Cyprus Holdings Public Limited Company ("BOCH" and, together with its subsidiaries, the "Group") announces that it has received approval from the ECB for the Significant Risk Transfer ("SRT") benefit from the Transaction.

This is an important step towards completion of the Transaction, which remains subject to various outstanding conditions precedent1. Completion is currently expected to occur in early 2Q2019.

As previously reported, the Transaction reduces the Group's non-performing exposures (NPEs) by €2.7 bn and improves the NPE ratio from 47% to 36%3. The NPE provisioning coverage ratio pro forma for the Transaction stands at 47%3.

On completion, the derecognition of the Helix portfolio is expected to have a positive impact on the capital ratios of 160 basis points2, resulting from the release of risk weighted assets.

As at 31 December 2018, as previously reported, the Group's phased-in CET1 ratio and Total capital ratio, pro forma for both DTC2 and Helix, stood at 15.4% and 18.3% respectively.

For further information, please contact Investor Relations at investors@bankofcyprus.com.

[1] Further to the announcement of 28 August 2018 and updates provided with the publication of the Group financial results for the nine months ended 30 September 2018 and the preliminary Group financial results for the year ended 31 December 2018

2 Refer to slide 36 of the presentation for the preliminary Group financial results for the year ended 31 December 2018 published on 4 March 2019

3 Based on the preliminary Group financial results for the year ended 31 December 2018

4 DTC refers to the amendments in the legislation adopted by the Cyprus Parliament on 1 March 2019 and was published on the Official Gazette of the Republic on 15 March 2019

 

 

Group Profile

 

The Bank of Cyprus Group is the leading banking and financial services group in Cyprus, providing a wide range of financial products and services which include retail and commercial banking, finance, factoring, investment banking, brokerage, fund management, private banking, life and general insurance. The Bank of Cyprus Group operates through a total of 112 branches in Cyprus. Bank of Cyprus also has representative offices in Russia, Ukraine and China. The Bank of Cyprus Group employs 4,146 staff worldwide. At 31 December 2018, the Group's Total Assets amounted to €22.1 bn and Total Equity was €2.4 bn. The Bank of Cyprus Group comprises Bank of Cyprus Holdings Public Limited Company, its subsidiary Bank of Cyprus Public Company Limited and its subsidiaries.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FURLLFLEVVIALIA
Date   Source Headline
20th Nov 20239:58 amRNSAppointment of New Director
13th Nov 20237:00 amRNSDoc re. (9M2023 Investor Presentation)
13th Nov 20237:00 amRNS9M2023 Group Financial Results
27th Oct 20237:17 amRNSDate of announcement of 9M2023 FR
24th Oct 202312:41 pmRNSTR1 Notification - Caius
13th Oct 202312:27 pmRNSChanges in the composition of the BODs
27th Sep 20238:28 amRNSDirectorate Change
31st Aug 20237:37 amRNSChanges in the composition of BOD
11th Aug 20239:55 amRNSAppointment of new director
21st Jul 202310:43 amRNSDate of announcement of 1H2023 FR
18th Jul 20234:43 pmRNSIssue of Senior Preferred Notes
3rd Jul 202311:48 amRNSBuyback of Additional Tier 1 Capital Securities
23rd Jun 202312:48 pmRNSComposition of the Boards of Directors
20th Jun 202312:22 pmRNSResults of Additional Tier 1 Tender Cash Offer
19th Jun 202312:34 pmRNSTR1 Notification of Major Holdings - Caius
13th Jun 20233:43 pmRNSRefinancing of AT1 Capital Securities
12th Jun 202311:36 amRNSPDMR Notification of Transaction – Iordanou
12th Jun 20239:40 amRNSLaunch of Cash Tender Offer for AT1 Cap.Securities
12th Jun 20238:39 amRNSPDMR Notification of Transaction – Iordanou
8th Jun 20239:01 amRNSDoc re. (Investor Presentation Update)
8th Jun 20239:00 amRNSAnnouncement for the Investor Update Event
30th May 20237:00 amRNSTR1 Notification of Major Holdings -Eaton Vance
26th May 20235:57 pmRNSResult of AGM-Replacement
26th May 202312:41 pmRNSBoard Election and Board Committees composition
26th May 202312:35 pmRNSResolutions of AGM
16th May 20237:01 amRNSDoc re. (1Q2023 Investor Presentation)
16th May 20237:00 amRNS1Q2023 Group Financial Results
11th May 20238:56 amRNSInvestor Update event scheduled for 8 June 2023
9th May 202312:24 pmRNSAppointment of Additional Corporate Broker
5th May 20239:16 amRNSDate of announcement of 1Q2023 FR
25th Apr 202310:52 amRNSNotice of AGM 2023
19th Apr 20237:06 amRNSTR1 Notification of Holdings -Eaton Vance
13th Apr 20231:44 pmRNSResumption of dividend payments
5th Apr 202311:51 amRNSDoc re. (2022 Pillar 3 Disclosures)
3rd Apr 202310:07 amRNSChanges in the composition of the Boards
31st Mar 202312:54 pmRNSBOC Annual Financial Report 2022 Announcement
31st Mar 202312:50 pmRNSBOCH Annual Financial Report 2022 Announcement
31st Mar 202312:49 pmRNSFY2022 Group Financial Results
31st Mar 202312:46 pmRNSDoc re. (FY2022 Investor Presentation)
21st Mar 202311:02 amRNSDate of announcement of the Audited FR FY2022
20th Feb 202312:12 pmRNSNomination for appoint. to the Board of Directors
20th Feb 20237:04 amRNSPreliminary FY2022 Group Financial Results
20th Feb 20237:02 amRNSDoc re. (Prelim FY2022 Investor Presentation)
8th Feb 20237:04 amRNSAppointment of Additional Corporate Broker
3rd Feb 202310:51 amRNSDate of announcement of PrelimFY2022 FR
9th Jan 20237:00 amRNSTR1 Notification of Major Holdings -Senvest
30th Dec 20227:33 amRNSLong Term Incentive Plan
23rd Dec 20229:15 amRNSPDMR Notification of Transaction – Iordanou
16th Dec 20221:54 pmRNSExtension of appointment of Group CEO
16th Dec 20228:05 amRNSDate of Annual General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.